Valuation: Synovics Pharmaceuticals, Inc.

Market Cap 16.41L 14.31L 13.51L 12.27L 22.98L 16Cr 23.08L 1.62Cr 62.44L 8Cr 61.63L 60.26L 26Cr P/E 2007
-0.73x
P/E 2008 -2.06x
Enterprise Value 81.29L 70.88L 66.93L 60.78L 1.14Cr 78Cr 1.14Cr 8.02Cr 3.09Cr 40Cr 3.05Cr 2.99Cr 127.6Cr EV / Sales 2007
1.81x
EV / Sales 2008 0.6x
Free-Float
95.75%
Yield 2007 *
-
Yield 2008 -
1 day-50.00%
6 months+9,900.00%
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-.--%-.--%-.--% 3.65T
+0.04%+3.34%+51.12%+101.82% 1,02800Cr
-0.09%+1.66%+55.02%+66.18% 65TCr
-0.02%+2.66%+18.91%+71.47% 47TCr
-1.22%+3.66%+36.44%+38.32% 35TCr
-0.79%+2.73%+19.03%+25.08% 27TCr
+0.58%+6.76%+11.13%+16.52% 26TCr
+1.55%+2.20%+39.81%+46.55% 21TCr
+0.79%+1.84%-28.27%-56.71% 19TCr
-0.52%+4.45%+32.12%+98.51% 19TCr
Average -4.82%+2.93%+23.53%+40.77% 36.02TCr
Weighted average by Cap. +0.23%+3.09%+35.15%+61.76%

Financials

2007 2008
Net sales 2.35Cr 2.05Cr 1.93Cr 1.75Cr 3.29Cr 225.17Cr 3.3Cr 23Cr 8.93Cr 114.48Cr 8.82Cr 8.62Cr 368.35Cr 2.6Cr 2.26Cr 2.14Cr 1.94Cr 3.64Cr 249.1Cr 3.65Cr 26Cr 9.88Cr 126.64Cr 9.75Cr 9.54Cr 407.49Cr
Net income -2.09Cr -1.82Cr -1.72Cr -1.56Cr -2.92Cr -200.14Cr -2.93Cr -21Cr -7.94Cr -101.75Cr -7.84Cr -7.66Cr -327.41Cr -40.06L -34.93L -32.98L -29.95L -56.12L -38Cr -56.35L -3.95Cr -1.52Cr -20Cr -1.5Cr -1.47Cr -63Cr
Net Debt 1.88Cr 1.64Cr 1.55Cr 1.4Cr 2.63Cr 180.3Cr 2.64Cr 19Cr 7.15Cr 92Cr 7.06Cr 6.9Cr 294.95Cr 64.88L 56.58L 53.42L 48.51L 90.89L 62Cr 91.27L 6.4Cr 2.47Cr 32Cr 2.44Cr 2.38Cr 101.85Cr
Logo Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Employees
155
  1. Stock Market
  2. Stocks
  3. SYVC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!